Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease

Table 2

The clinical characteristics of active CD patients.

	Response group	Failure group
Patients	19	13
Age, years (range)	(18-57)	(20-61)
Gender (M/F)	9/10	5/8
Medical therapy received
5-ASA	12	7
Immunosuppressants	7	6
Biologics	0	0
Disease location
Ileum only (L1)	4	3
Colon only (L2)	8	6
Ileum and colon (L3)	2	1
Upper gastrointestinal tract (L4a)	5	3
Disease duration (months)
Smoking history (months)